Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells.

Al-Dhaheri M, Wu J, Skliris GP, Li J, Higashimato K, Wang Y, White KP, Lambert P, Zhu Y, Murphy L, Xu W.

Cancer Res. 2011 Mar 15;71(6):2118-28. doi: 10.1158/0008-5472.CAN-10-2426. Epub 2011 Jan 31.

2.

PELP1 oncogenic functions involve CARM1 regulation.

Mann M, Cortez V, Vadlamudi R.

Carcinogenesis. 2013 Jul;34(7):1468-75. doi: 10.1093/carcin/bgt091. Epub 2013 Mar 13.

3.

The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer.

Habashy HO, Rakha EA, Ellis IO, Powe DG.

Breast Cancer Res Treat. 2013 Jul;140(2):307-16. doi: 10.1007/s10549-013-2614-y. Epub 2013 Jul 26.

PMID:
23887673
4.

Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer.

Andruska N, Zheng X, Yang X, Helferich WG, Shapiro DJ.

Oncogene. 2015 Jul;34(29):3760-9. doi: 10.1038/onc.2014.292. Epub 2014 Sep 29.

5.

Novel CARM1-Interacting Protein, DZIP3, Is a Transcriptional Coactivator of Estrogen Receptor-α.

Purcell DJ, Chauhan S, Jimenez-Stinson D, Elliott KR, Tsewang TD, Lee YH, Marples B, Lee DY.

Mol Endocrinol. 2015 Dec;29(12):1708-19. doi: 10.1210/me.2015-1083. Epub 2015 Oct 27.

6.

The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.

Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, Prossnitz ER, Dun NJ, Jordan VC.

Cancer Res. 2010 Feb 1;70(3):1184-94. doi: 10.1158/0008-5472.CAN-09-3068. Epub 2010 Jan 19.

7.

Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.

Syed Khaja AS, Dizeyi N, Kopparapu PK, Anagnostaki L, Härkönen P, Persson JL.

PLoS One. 2013 Aug 8;8(8):e72210. doi: 10.1371/journal.pone.0072210. eCollection 2013.

8.
9.

Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.

Konduri SD, Medisetty R, Liu W, Kaipparettu BA, Srivastava P, Brauch H, Fritz P, Swetzig WM, Gardner AE, Khan SA, Das GM.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15081-6. doi: 10.1073/pnas.1009575107. Epub 2010 Aug 9.

10.

Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.

Tolhurst RS, Thomas RS, Kyle FJ, Patel H, Periyasamy M, Photiou A, Thiruchelvam PT, Lai CF, Al-Sabbagh M, Fisher RA, Barry S, Crnogorac-Jurcevic T, Martin LA, Dowsett M, Charles Coombes R, Kamalati T, Ali S, Buluwela L.

Breast Cancer Res Treat. 2011 Jul;128(2):357-68. doi: 10.1007/s10549-010-1122-6. Epub 2010 Aug 22.

PMID:
20730598
11.

Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.

Karam M, Bièche I, Legay C, Vacher S, Auclair C, Ricort JM.

J Cell Mol Med. 2014 Dec;18(12):2536-52. doi: 10.1111/jcmm.12322. Epub 2014 Oct 7.

12.

Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy.

Liu W, Ip MM, Podgorsak MB, Das GM.

Breast Cancer Res Treat. 2009 May;115(1):43-50. doi: 10.1007/s10549-008-0044-z. Epub 2008 May 15.

13.

Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.

Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW, Sonenshein G, Osborne BA, Miele L.

Oncogene. 2010 Jan 14;29(2):201-13. doi: 10.1038/onc.2009.323. Epub 2009 Oct 19.

14.

RBCK1 drives breast cancer cell proliferation by promoting transcription of estrogen receptor alpha and cyclin B1.

Gustafsson N, Zhao C, Gustafsson JA, Dahlman-Wright K.

Cancer Res. 2010 Feb 1;70(3):1265-74. doi: 10.1158/0008-5472.CAN-09-2674. Epub 2010 Jan 26.

15.

Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.

Chen B, Gajdos C, Dardes R, Kidwai N, Johnston SR, Dowsett M, Jordan VC.

Int J Oncol. 2005 Aug;27(2):327-35.

PMID:
16010412
16.

CARM1 regulates estrogen-stimulated breast cancer growth through up-regulation of E2F1.

Frietze S, Lupien M, Silver PA, Brown M.

Cancer Res. 2008 Jan 1;68(1):301-6. doi: 10.1158/0008-5472.CAN-07-1983.

17.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

18.

Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status.

Harrison H, Rogerson L, Gregson HJ, Brennan KR, Clarke RB, Landberg G.

Cancer Res. 2013 Feb 15;73(4):1420-33. doi: 10.1158/0008-5472.CAN-12-2505. Epub 2012 Dec 17.

19.

Estrogen receptor α mediates proliferation of breast cancer MCF-7 cells via a p21/PCNA/E2F1-dependent pathway.

Liao XH, Lu DL, Wang N, Liu LY, Wang Y, Li YQ, Yan TB, Sun XG, Hu P, Zhang TC.

FEBS J. 2014 Feb;281(3):927-42. doi: 10.1111/febs.12658. Epub 2014 Jan 2.

20.

A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells.

Williams C, Edvardsson K, Lewandowski SA, Ström A, Gustafsson JA.

Oncogene. 2008 Feb 7;27(7):1019-32. Epub 2007 Aug 13.

PMID:
17700529

Supplemental Content

Support Center